Astellas Pharma Incorporated operates in the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Astellas Pharma Incorporated with three other
companies in this sector in Japan:
Daiichi Sankyo Company Limited
sales of 955.12 billion Japanese Yen [US$8.51 billion]
of which 93%
was prescription drugs),
Eisai Company Limited
(539.10 billion Japanese Yen [US$4.80 billion]
of which 54%
was Pharmaceutical Business -Japan), and
Takeda Pharmaceutical Company Limited
(1.73 trillion Japanese Yen [US$15.43 billion]
of which 91%
was Pharmaceutical Business).
Astellas Pharma Incorporated reported sales of ¥1.31 trillion (US$11.69 billion)
March of 2017.
decrease of 4.4%
versus 2016, when the company's sales were ¥1.37 trillion.
Contributing to the drop in overall sales was the 14.4% decline
in Vesicare, from ¥135.64 billion to ¥116.08 billion.
There were also decreases in sales in
Other (down 3.1% to ¥757.36 billion)
Prograf (down 8.5% to ¥186.16 billion)
However, these declines were partially offset by the increase in sales of
Xtandi (up 0.0% to ¥252.08 billion)